Latest News

New variant jumps to second place on COVID list


 

The new COVID-19 strain known as “Arcturus” has increased in the United States so much that it has been added to the Centers for Disease and Control’s watch list.

Officially labeled XBB.1.16, Arcturus is a subvariant of Omicron that was first seen in India and has been on the World Health Organization’s watchlist since the end of March. The CDC’s most recent update now lists Arcturus as causing 7% of U.S. coronavirus cases, landing it in second place behind its long-predominant Omicron cousin XBB.1.5, which causes 78% of cases.

Arcturus is more transmissible but not more dangerous than recent chart-topping strains, experts say.

“It is causing increasing case counts in certain parts of the world, including India. We’re not seeing high rates of XBB.1.16 yet in the United States, but it may become more prominent in coming weeks,” Mayo Clinic viral disease expert Matthew Binnicker, PhD, told The Seattle Times.

Arcturus has been causing a new symptom in children, Indian medical providers have reported.

“One new feature of cases caused by this variant is that it seems to be causing conjunctivitis, or red and itchy eyes, in young patients,” Dr. Binnicker said. “This is not something that we’ve seen with prior strains of the virus.”

More than 11,000 people in the United States remained hospitalized with COVID at the end of last week, and 1,327 people died of the virus last week, CDC data show. To date, 6.9 million people worldwide have died from COVID, the WHO says. Of those deaths, more than 1.1 million occurred in the U.S.

A version of this article originally appeared on WebMD.com.

Recommended Reading

Leading for High Reliability During the COVID-19 Pandemic: A Pilot Quality Improvement Initiative to Identify Challenges Faced and Lessons Learned
Journal of Clinical Outcomes Management
COVID led to rise in pregnancy-related deaths: New research
Journal of Clinical Outcomes Management
High-dose prophylactic anticoagulation benefits patients with COVID-19 pneumonia
Journal of Clinical Outcomes Management
Nasal COVID treatment shows early promise against multiple variants
Journal of Clinical Outcomes Management
SARS-CoV-2 crosses placenta and infects brains of two infants: ‘This is a first’
Journal of Clinical Outcomes Management
Long COVID hitting some states, minorities, women harder
Journal of Clinical Outcomes Management
Parents of patients with rheumatic disease, MIS-C strongly hesitant of COVID vaccination
Journal of Clinical Outcomes Management
Long COVID: ‘On par’ with heart disease, cancer, book says
Journal of Clinical Outcomes Management
COVID caused 4.6-year drop in NYC life expectancy
Journal of Clinical Outcomes Management
As COVID tracking wanes, are we letting our guard down too soon?
Journal of Clinical Outcomes Management